Ingredient news
Shatavari Study Reports Time-Dependent Signals in Perimenopause Research
By Nutranexa News |
A NutraIngredients report describes a study of Aspurus Shatavari extract in perimenopausal women and emphasizes the timing of reported symptom changes.
What Was Reported
NutraIngredients reported that a study of Aspurus Shatavari extract in perimenopausal women described symptom improvements within four weeks and maximum relief by 12 weeks. The report refers to a specific extract, study population, dose, and endpoint set.
A result for a branded botanical extract cannot be transferred to phosphatidylserine or to a different finished formula. It also does not by itself establish a permitted health claim in a destination market.
Ingredient Buyer Context
Ingredient teams should ask for the primary publication, intervention identity, dose, comparator, population, endpoints, and statistical limitations before using a study in a product brief. The same evidence discipline applies when a brand evaluates PS research or prepares non-medical formulation language.
The source concerns the named study, company, agency, or market development. It should not be expanded into a medical treatment claim, a universal ingredient result, or a guarantee about a supplier or finished product.
Nutranexa Takeaway
Nutranexa does not supply Shatavari and does not endorse treatment claims. This brief is included as a reminder to separate ingredient-specific evidence from general category language.
For a product-specific discussion, provide the target market, application, source preference, PS grade, annual quantity, packaging, and required documents. Nutranexa can then discuss the relevant product and quality evidence without assuming facts that are not in the current controlled file.